Cover Image
市場調查報告書

再生醫療的全球市場:分析、預測

Global Regenerative Medicines Market - Analysis and Forecast 2017-2025: Focus on Therapy, Applications, Market Share Analysis, 22 Country Analysis, and Competitive Landscape

出版商 BIS Research Private Limited 商品編碼 600641
出版日期 內容資訊 英文 257 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
再生醫療的全球市場:分析、預測 Global Regenerative Medicines Market - Analysis and Forecast 2017-2025: Focus on Therapy, Applications, Market Share Analysis, 22 Country Analysis, and Competitive Landscape
出版日期: 2018年01月22日 內容資訊: 英文 257 Pages
簡介

本報告提供全球再生醫療市場調查,市場概要和主要的促進、阻礙因素,市場競爭環境,市場規模趨勢預測,各治療方法、產品、用途、地區的趨勢,主要企業等相關詳細分析。

摘要整理

第1章 調查範圍

第2章 市場概要

  • 簡介
  • 發展歷史
  • 現在、未來

第3章 市場動態

  • 市場成長的促進因素
  • 市場課題
  • 市場機會

第4章 競爭情形

  • 主要的發展 & 策略的佔有率
  • 市場佔有率分析
  • 波特的五力分析

第5章 全球再生醫療市場:各治療法

  • 細胞療法
  • 遺傳基因療法
  • 人組織工程

第6章 全球再生醫療市場:各產品

  • 簡介
  • 無細胞產品
  • 細胞產品
  • 產品
  • 開發中產品

第7章 全球再生醫療市場:各用途

  • 簡介
  • 整形外科 & 牙科
  • 心臟病
  • 創傷治療
  • 糖尿病
  • 癌症免疫
  • 其他

第8章 全球再生醫療市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 其他 (RoW)

第9章 企業簡介

目錄
Product Code: BH043A

The regenerative medicines market generated $17.03 billion revenue in 2016. The North America regenerative medicines market currently holds 39% percent of the global regenerative medicines market. Technological innovations across the various segments of the regenerative medicine have propelled growth in the recent past in the region.

Due to the fall of the fertility rates, and increased life expectancy, the world population is ageing rapidly. The prevalence of diseases such as diabetes, osteoarthritis, cardiovascular diseases, Alzheimer's, and many others, are higher among the elderly. As per the Arthritis Foundation, the older population in the U.S. affected by arthritis is estimated to grow to 21% by 2040, from the current value of 15%. The rising prevalence of chronic diseases is another factor contributing to the growth of the market. In the recent years, the prevalence of chronic diseases has been increasing irrespective of the age. As per WHO, the global prevalence of diabetes increased to 8.5% in adults over the age of 18 years in 2014 from 4.7% in 1980. The prevalence of genetic diseases, and cancer has also witnessed a rise in the recent years.

Regenerative medicine presents with opportunities to change the treatment options, and offers complete cure of the diseases. The pharmaceutical industry is witnessing the growth of pipeline of candidates for regenerative medicine. A number of companies are now indulging in the research and development of such therapies.

The regenerative medicine market includes various cellular, and acellular products. The market involves various therapies such as gene therapy, cell therapy, and tissue engineering. This therapy is being applied to a number of diseases, and therapeutic areas such as orthopaedic, cardiovascular, wound healing, diabetes, neurodegenerative, immune-oncology, and others. The market analysis includes an in-depth examination of the key ecosystem players, and the key strategies and developments taking place in this market. Additionally, it includes market dynamics (market drivers, opportunities, and challenges), and industry analysis.

The purpose of the study is to gain a holistic view of the regenerative medicine market in terms of various factors influencing it such as recent trends, technological advancements, and regulatory aspects of the market. The scope of this report is centred upon conducting a detailed study of the solutions allied with the regenerative medicine market. The market has been segmented into ‘product', ‘therapy', ‘application', and ‘geographical regions'. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market, and helps in forming well informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into the consideration before entering the market.

This research report aims at answering various aspects of the global regenerative medicine market with the help of the key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The study considers the growth-share matrix model for a comprehensive study of the global regenerative medicine market, and assesses the factors governing the same.

The answers to the following key questions can be derived from this report:

  • What are the major market drivers, challenges, and opportunities in the global regenerative medicine market?
  • How did the regenerative medicine market evolve, and what is its scope in the future?
  • What is the market share of the leading segments, and sub-segments of the global regenerative medicine market in 2017 and 2025?
  • How will each segment of the global regenerative medicine market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2025?
  • What are the influencing factors that may affect the market share of the key players?
  • How will the industry evolve during the forecast period 2017-2025?
  • What are the key developmental strategies implemented by the key players to stand out in this market?
  • What will be the growth rate of the tissue engineering segment during the forecast period?
  • Which therapy segment is expected to register the highest CAGR for the regenerative medicine market?
  • How has the market been segmented on the basis of application? Which application segment has the largest share, and growth rate in the regenerative medicine market?
  • What will be the value of immune-oncology segment by 2025?
  • Which geographical location will contribute to the highest sales of regenerative medicine?

The key players that have been contributing significantly to the regenerative medicine market are Novartis AG, ViaCyte, Inc., Vericel Corporation, Tissue Regenix, Osiris Therapeutics, Inc., NuVasive, Inc., MiMedx Group Inc., Mesoblast Limited, Acelity, and Cytori Therapeutics, among others.

Table of Contents

Executive Summary

1. Report Scope

  • 1.1. Scope of the Report
  • 1.2. Global Regenerative Medicine Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Data Triangulation
    • 1.3.2. Key Data Points From Secondary Sources
    • 1.3.3. Key Data Points From Primary Sources
    • 1.3.4. Top-Down Approach (Segmental Analysis)
    • 1.3.5. Bottom-Up Approach (Segmental Analysis)
    • 1.3.6. Assumptions and Limitations
    • 1.3.7. Data and Prediction Modelling

2. Market Overview

  • 2.1. Introduction
  • 2.2. Evolutionary History
  • 2.3. Present And Future

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Challenges
  • 3.3. Market Opportunities

4. Competitive Landscape

  • 4.1. Share of Key Developments & Strategies
  • 4.2. Market Share Analysis
  • 4.3. Porter's Five Force Analysis

5. Global Regenerative Medicines Market, by Therapy

  • 5.1. Cell Therapy
  • 5.2. Gene Therapy
  • 5.3. Tissue Engineering

6. Global Regenerative Medicines Market, by Product (Qualitative)

  • 6.1. Introduction
  • 6.2. . Acellular Products
  • 6.3. Cellular Products
  • 6.4. Products
  • 6.5. Pipeline Products

7. Global Regenerative Medicines Market, by Application

  • 7.1. Introduction
  • 7.2. Orthopaedic & Dental
  • 7.3. Cardiology
  • 7.4. Wound Healing
  • 7.5. Diabetes
  • 7.6. Immuno-Oncology
  • 7.7. Others

8. Global Regenerative Medicines Market, by Region

  • 8.1. Introduction
  • 8.2. North America
  • 8.3. Europe
  • 8.4. Asia Pacific
  • 8.5. Rest of the World

9. Company Profiles

  • 9.1. Acelity
    • 9.1.1. Overview
    • 9.1.2. Product Portfolio
    • 9.1.3. Financials
      • 9.1.3.1. Financial Summary
    • 9.1.4. Acelity: SWOT Analysis
  • 9.2. Athersys, Inc.
    • 9.2.1. Overview
    • 9.2.2. Product Pipeline
    • 9.2.3. Financials
      • 9.2.3.1. Financial Summary
    • 9.2.4. Athersys, Inc.: SWOT Analysis
  • 9.3. . Cellular Biomedicine Group, Inc.
    • 9.3.1. Overview
    • 9.3.2. Product Pipeline
    • 9.3.3. Financials
    • 9.3.4. Cellular Biomedicine Group, Inc.: SWOT Analysis
  • 9.4. . Cytori Therapeutics
    • 9.4.1. Overview
    • 9.4.2. Product Portfolio
    • 9.4.3. Financials
      • 9.4.3.1. Financial Summary
    • 9.4.4. Cytori Therapeutics: SWOT Analysis
  • 9.5. Integra Lifesciences Corporation
    • 9.5.1. Overview
    • 9.5.2. Product Portfolio
    • 9.5.3. Financials
      • 9.5.3.1. Financial Summary
    • 9.5.4. Integra Lifesciences Corporation: SWOT Analysis
  • 9.6. Mesoblast Limited
    • 9.6.1. Overview
    • 9.6.2. Product Portfolio
    • 9.6.3. Financials
      • 9.6.3.1. Financial Summary
    • 9.6.4. Mesoblast Limited: SWOT Analysis
  • 9.7. MiMedx Group Inc.
    • 9.7.1. Overview
    • 9.7.2. Product Portfolio
    • 9.7.3. Financials
      • 9.7.3.1. Financial Summary
    • 9.7.4. MiMedx Group Inc.: SWOT Analysis
  • 9.8. Novartis International AG
    • 9.8.1. Overview
    • 9.8.2. Product Portfolio
    • 9.8.3. Financials
      • 9.8.3.1. Financial Summary
    • 9.8.4. Novartis International AG: SWOT Analysis
  • 9.9. NuVasive, Inc.
    • 9.9.1. Overview
    • 9.9.2. Product Portfolio
    • 9.9.3. Financials
      • 9.9.3.1. Financial Summary
    • 9.9.4. Nuvasive, Inc: SWOT Analysis
  • 9.10. Organogenesis Inc.
    • 9.10.1. Overview
    • 9.10.2. Product Portfolio
    • 9.10.3. Corporate Summary
    • 9.10.4. Organogenesis Inc.: SWOT Analysis
  • 9.11. OSIRIS THERAPEUTICS, INC.
    • 9.11.1. Overview
    • 9.11.2. Product Portfolio
    • 9.11.3. Financials
      • 9.11.3.1. Financial Summary
    • 9.11.4. OSIRIS THERAPEUTICS, INC.: SWOT Analysis
  • 9.12. STRYKER CORPORATION
    • 9.12.1. Overview
    • 9.12.2. Product Portfolio
    • 9.12.3. Financials
      • 9.12.3.1. Financial Summary
    • 9.12.4. STRYKER CORPORATION: SWOT Analysis
  • 9.13. TERUMO CORPORATION
    • 9.13.1. Overview
    • 9.13.2. Product Portfolio
    • 9.13.3. Financials
      • 9.13.3.1. Financial Summary
    • 9.13.4. TERUMO CORPORATION: SWOT Analysis
  • 9.14. TiGenix
    • 9.14.1. Overview
    • 9.14.2. Product Pipeline
    • 9.14.3. Financials
      • 9.14.3.1. Financial Summary
    • 9.14.4. TiGenix: SWOT Analysis
  • 9.15. Tissue Regenix
    • 9.15.1. Overview
    • 9.15.2. Product Portfolio & Product Pipeline
    • 9.15.3. Financials
      • 9.15.3.1. Financial Summary
    • 9.15.4. Tissue Regenix: SWOT Analysis
  • 9.16. Vericel Corporation
    • 9.16.1. Overview
    • 9.16.2. Product Portfolio
    • 9.16.3. Financials
      • 9.16.3.1. Financial Summary
    • 9.16.4. Vericel Corporation: SWOT Analysis
  • 9.17. ViaCyte, Inc.
    • 9.17.1. Overview
    • 9.17.2. Product Pipeline
    • 9.17.3. Corporate Summary
    • 9.17.4. ViaCyte, Inc.: SWOT Analysis
  • 9.18. Zimmer Biomet Holdings Inc
    • 9.18.1. Overview
    • 9.18.2. Product Portfolio
    • 9.18.3. Financials
      • 9.18.3.1. Financial Summary
    • 9.18.4. Zimmer Biomet Holdings Inc: SWOT Analysis
  • 9.19. Anika Therapeutics
  • 9.20. Capricor Therapeutics
  • 9.21. COOK BIOTECH, INC.
  • 9.22. Gamida Cell
  • 9.23. Juno Therapeutics

List of Tables

  • 1. Global Regenerative Medicines Market (2016 & 2025)
  • 2. Comparison of Regenerative Medicines Market: China vs U.S.
  • 3. Key Regional Markets for Regenerative Medicines
  • 4. Percentage of Total Regional Population Aged 65 Years & Above: 2015 & 2030
  • 5. Market Share Analysis, 2015-2017
  • 6. Factors Affecting the Bargaining Power of Suppliers
  • 7. Factors Affecting the Bargaining Power of Buyers
  • 8. Factors Affecting Threat of New Entrants
  • 9. Factors Affecting the Threat of Substitutes
  • 10. Factors Affecting the Intensity of Competitive Rivalry
  • 11. Global Stem Cells Market, by Country, 2016-2025 ($Million)
  • 12. Global Gene Therapy Market, by Country, 2016-2025 ($Million)
  • 13. Global Tissue Engineering Market, by Product Type, 2016-2025 ($Million)
  • 14. Global Tissue Engineering Market, by Country, 2016-2025 ($Million)
  • 15. Some of the Approved Regenerative Medicine Products
  • 16. Products In The Pipeline
  • 17. Overview: Acelity
  • 18. Overview: Athersys, Inc.
  • 19. Overview: Cellular Biomedicine Group, Inc.
  • 20. Product Pipeline: Cellular Biomedicine Group, Inc.
  • 21. Overview: Cytori Therapeutics
  • 22. Overview: Integra LifeSciences Corporation
  • 23. Overview: Mesoblast
  • 24. Product Portfolio: Mesoblast
  • 25. Overview: MiMedx Group Inc.
  • 26. Overview: Novartis International AG
  • 27. Overview: NuVasive, Inc.
  • 28. Overview: Organogenesis Inc.
  • 29. Overview: OSIRIS THERAPEUTICS, INC.
  • 30. Overview: Stryker Corporation
  • 31. Overview: Terumo Corporation
  • 32. Overview: TiGenix
  • 33. Product Pipeline: TiGenix
  • 34. Overview: Tissue Regenix
  • 35. Overview: Vericel Corporation
  • 36. Overview: ViaCyte, Inc.
  • 37. Product Pipeline: ViaCyte, Inc.
  • 38. Overview: Zimmer Biomet Holdings Inc.
  • 39. Overview: Anika Therapeutics, Inc.
  • 40. Overview: Capricor Therapeutics
  • 41. Overview: COOK BIOTECH, INC.
  • 42. Overview: Gamida Cell
  • 43. Overview: Juno Therapeutics

List of Figures

  • 1. Regenerative Medicines Industry Sectors
  • 2. Regenerative Medicines in Healthcare system
  • 3. The Global Regenerative Medicines Market ($Billion)
  • 4. Key Opportunities
  • 5. Impact Analysis
  • 6. Chronic Conditions: Key Statistics: 2016
  • 7. Global Regenerative Medicines Market, by Therapy Type ($Million)
  • 8. Global Regenerative Medicines Market, by Therapy, 2016
  • 9. Global Regenerative Medicines Market, by Therapy, 2025
  • 10. Evolution of Tissue Engineered Products
  • 11. Tissue Engineered Therapy Market, by Product Type ($Billion)
  • 12. Global Regenerative Medicines Market, by Application, 2016
  • 13. Global Regenerative Medicines Market, by Application, 2025
  • 14. Global Regenerative Medicines Market Value, by Region, 2016 & 2025 ($Billion)
  • 15. Global Regenerative Medicines Market, by Region, 2016
  • 16. Global Regenerative Medicines Market, by Region, 2025
  • 17. Competitive Landscape: Global Regenerative Medicines Market
  • 18. Global Regenerative Medicines Market Share Analysis: 2016
  • 19. Importance of sustainability criteria from a industry (Manufacturer) point of view
  • 20. Global Regenerative Medicines Market Segmentation
  • 21. Research Methodology
  • 22. Data Triangulation
  • 23. Key Data Points From Secondary Sources
  • 24. Key Data Points From Primary Sources
  • 25. Top-Down Approach (Segment wise Analysis)
  • 26. Bottom-Up Approach (Segmental Analysis)
  • 27. Assumptions and Limitations
  • 28. Data and Prediction Modelling
  • 29. Regenerative Medicine Types
  • 30. Evolutionary History
  • 31. The Present and Future of Regenerative Medicine
  • 32. Market Dynamics
  • 33. Share of Different Strategies in the Market
  • 34. Porter's Five Forces Analysis
  • 35. Global Regenerative Medicines Market, By Therapy, 2016-2023 ($Million)
  • 36. Some Of The Strategies Of Cell Therapy
  • 37. Types of Cell Therapy
  • 38. Types of Stem Cells
  • 39. Global Stem Cell Market, 2016-2025 ($Billion)
  • 40. Global Stem Cells Market, by Type, 2016-2025 ($Billion)
  • 41. Cord Blood Banking Market, 2016-2025 ($Billion)
  • 42. Stem Cells & Services Market, 2016-2025 ($Billion)
  • 43. Global Stem Cell Therapies Market, 2016-2025 ($Billion)
  • 44. Global Stem Cells Market, by region, 2016-2025 ($Million)
  • 45. Types of Gene Therapy
  • 46. Gene Therapy Techniques
  • 47. Global Gene Therapy Market, 2016-2025 ($Million)
  • 48. Global Gene Therapy Market, by Region, 2016-2025 ($Million)
  • 49. Global Tissue Engineering Therapy Market, 2016-2025 ($Billion)
  • 50. Global Bone, Tendon, Cartilage, Allograft, and Autografts Market, 2016-2025 ($Million)
  • 51. Global Bone Graft Substitutes Market, 2016-2025 ($Million)
  • 52. Global Bone Growth Factors and Spinal Stimulation Market, 2016-2025 ($Million)
  • 53. Global Demineralised Bone Matrix Market, 2016-2025 ($Million)
  • 54. Global Bone Morphogenetic Proteins Market, 2016-2025 ($Million)
  • 55. Global Other Orthobiologics Market, 2016-2025 ($Million)
  • 56. Global Platelet Rich Plasma Market, 2016-2025 ($Million)
  • 57. Global Skin/Dermal Substitutes (Allo/Autografts) Market, 2016-2025 ($Million)
  • 58. Global Bioengineered Skin/ Synthetic Substitutes Market, 2016-2025 ($Million)
  • 59. Global Placenta/Amniotic Tissue Market, 2016-2025 ($Million)
  • 60. Global Growth Factors Market, 2016-2025 ($Million)
  • 61. Global Topical Biologics Market, 2016-2025 ($Million)
  • 62. Global Tissue Heart Valves Market, 2016-2025 ($Million)
  • 63. Global Vascular Synthetic Grafts and Patches Market, 2016-2025 ($Million)
  • 64. Global Tissue Composits Market, 2016-2025 ($Million)
  • 65. Global Others Market, 2016-2025 ($Million)
  • 66. Types of Products
  • 67. Global Regenerative Medicines Market, by Application
  • 68. Global Regenerative Medicines Market, by Application, 2016-2025 ($Billion)
  • 69. Types of Skin Regeneration
  • 70. Types of Diabetes Mellitus
  • 71. Regenerative Medicine In Oncology
  • 72. Global Regenerative Medicines Market, by region
  • 73. Global Regenerative Medicines Market, by region 2016-2025 ($Billion)
  • 74. The U.S. Regenerative Medicines Market, 2016-2025 ($Million)
  • 75. The U.S. Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
  • 76. Canada Regenerative Medicines Market, 2016-2025 ($Million)
  • 77. Canada Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
  • 78. Germany Regenerative Medicines Market, 2016-2025 ($Million)
  • 79. Germany Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
  • 80. France Regenerative Medicines Market, 2016-2025 ($Million)
  • 81. France Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
  • 82. Italy Regenerative Medicines Market, 2016-2025 ($Million)
  • 83. Italy Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
  • 84. The U.K. Regenerative Medicines Market, 2016-2025 ($Million)
  • 85. The U.K. Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
  • 86. Spain Regenerative Medicines Market, 2016-2025 ($Million)
  • 87. Spain Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
  • 88. Netherlands Regenerative Medicines Market, 2016-2025 ($Million)
  • 89. The Netherlands Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
  • 90. Belgium Regenerative Medicines Market, 2016-2025 ($Million)
  • 91. Belgium Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
  • 92. Rest of Europe Regenerative Medicines Market, 2016-2025 ($Million)
  • 93. Rest of Europe Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
  • 94. Japan Regenerative Medicines Market, 2016-2025 ($Million)
  • 95. Japan Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
  • 96. China Regenerative Medicines Market, 2016-2025 ($Million)
  • 97. China Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
  • 98. South Korea Regenerative Medicines Market, 2016-2025 ($Million)
  • 99. South Korea Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
  • 100. Australia Regenerative Medicines Market, 2016-2025 ($Million)
  • 101. Australia Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
  • 102. India Regenerative Medicines Market, 2016-2025 ($Million)
  • 103. India Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
  • 104. Malaysia Regenerative Medicines Market, 2016-2025 ($Million)
  • 105. Malaysia Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
  • 106. Singapore Regenerative Medicines Market, 2016-2025 ($Million)
  • 107. Singapore Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
  • 108. Rest of Asia Regenerative Medicines Market, 2016-2025 ($Million)
  • 109. Rest of Asia Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
  • 110. Brazil Regenerative Medicines Market, 2016-2025 ($Million)
  • 111. Brazil Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
  • 112. Mexico Regenerative Medicines Market, 2016-2025 ($Million)
  • 113. Mexico Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
  • 114. Rest of LATAM Regenerative Medicines Market, 2016-2025 ($Million)
  • 115. Rest of LATAM Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
  • 116. KSA Regenerative Medicines Market, 2016-2025 ($Million)
  • 117. KSA Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
  • 118. Russia Regenerative Medicines Market, 2016-2025 ($Million)
  • 119. Russia Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
  • 120. Israel Regenerative Medicines Market, 2016-2025 ($Million)
  • 121. Israel Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
  • 122. The UAE Regenerative Medicines Market, 2016-2025 ($Million)
  • 123. The UAE Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
  • 124. Rest of World Regenerative Medicines Market, 2016-2025 ($Million)
  • 125. Rest of World Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
  • 126. Acelity: Product Portfolio
  • 127. Acelity: SWOT Analysis
  • 128. Athersys, Inc.: Product Pipeline
  • 129. Athersys, Inc.: SWOT Analysis
  • 130. Cellular Biomedicine Group, Inc.: SWOT Analysis
  • 131. Cytori Therapeutics: Product Portfolio
  • 132. Cytori Therapeutics: SWOT Analysis
  • 133. Integra LifeSciences Corporation: Product Portfolio
  • 134. Integra LifeSciences Corporation: SWOT Analysis
  • 135. Mesoblast Limited: SWOT Analysis
  • 136. MiMedx Group Inc.: Product Portfolio
  • 137. MiMedx Group Inc.: SWOT Analysis
  • 138. Novartis International AG: Product Portfolio
  • 139. NuVasive, Inc.: Product Portfolio
  • 140. NuVasive, Inc.: SWOT Analysis
  • 141. Organogenesis Inc: Product Portfolio
  • 142. Organogenesis Inc: SWOT Analysis
  • 143. OSIRIS THERAPEUTICS, INC.: Product Portfolio
  • 144. OSIRIS THERAPEUTICS, INC.: SWOT Analysis
  • 145. STRYKER CORPORATION: Product Portfolio
  • 146. STRYKER CORPORATION: SWOT Analysis
  • 147. TERUMO CORPORATION: Product Portfolio
  • 148. TERUMO CORPORATION: SWOT Analysis
  • 149. TiGenix: Product Portfolio
  • 150. TiGenix: SWOT Analysis
  • 151. Tissue Regenix: Product Portfolio
  • 152. Tissue Regenix Group plc: SWOT Analysis
  • 153. Vericel Corporation: Product Portfolio
  • 154. Vericel Corporation: SWOT Analysis
  • 155. Zimmer Biomet Holdings Inc: Product Portfolio
  • 156. Zimmer Biomet Holdings Inc: SWOT Analysis
Back to Top